Beta-interferon topical treatment in low and high risk cervical lesions.
In a series of 131 patients we evaluated the effects of medical therapy with beta-Interferon cream in patients with cervical Human Papilloma Virus (HPV) infection, which in some cases, was associated with CIN. Treatment consisted of the direct daily application of 1,000,000 IU beta-Interferon cream to colposcopically positive areas over a period of 15 days. At intervals of 1, 6, 12 and 24 months following treatment, cytohistological tests were carried out to assess the effects of treatment. At the 24-month control, the overall percentage for regression was 79.57% of cases. Regression was observed in 58.33% of patients with cytohistological changes associated with HPV without atypia, and in 69.85% of patients with HPV with atypia (38.9% total regression). The regression pattern for CIN lesions was as follows: in CIN lesions, regression occurred in 85.36%, in CIN II in 84.20%, and 37.5% of CIN III cases showed total regression.
Cinel
A
A
Service of Gynecologic Oncology and Cytodiagnostics, Institute of Gynecology, Padua University, Italy.
Wittenberg
L
L
Minucci
D
D
D000287:Administration, Topical; D000328:Adult; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016899:Interferon-beta / Q000008:administration & dosage*; D008875:Middle Aged; D027383:Papillomaviridae; D012074:Remission Induction; D014412:Tumor Virus Infections / Q000473:pathology / Q000628:therapy*; D002577:Uterine Cervical Diseases / Q000473:pathology / Q000628:therapy*
D016899:Interferon-beta